FI6 is a neutralizing antibody which binds and neutralizes both Group 1 and Group 2 human and animal influenza A viruses.
The researchers were able to culture single plasma cells in vitro, and screen plasma cells to isolate the rare ones which produced an antibody of unique specificity, by using the Humabs’ proprietary technology platform.
Humabs is in discussions with potential partners to take the antibody into the next stage of development.
Humabs CSO and IRB director Antonio Lanzavecchia said FI6 represents an important new treatment option and they look forward to take it through to the next stage of development.
"Furthermore, our proprietary antibody isolation platform is delivering a number of high quality preclinical, antibodies and we are building a pipeline in infectious and inflammatory diseases," Lanzavecchia said.